SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ / shares in Units, $ in Millions			1 Months Ended			2 Months Ended	3 Months Ended
	Mar. 18, 2020	Dec. 19, 2019	Jul. 23, 2018	Oct. 19, 2017	Oct. 31, 2015	May 31, 2020	Mar. 31, 2020	Mar. 31, 2019
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount							10,694,517	7,826,946
Net proceeds from private placement	$ 41.3
Subsequent Event [Member]
Significant Accounting Policies [Line Items]
Total proceeds from accounts receivable outstanding						$ 9.0
Total proceeds from accounts receivable outstanding - Chiesi						4.7
Subsequent Event [Member] | Alfataliglicerase [Member]
Significant Accounting Policies [Line Items]
Total proceeds from accounts receivable outstanding - Fiocruz						3.0
Subsequent Event [Member] | Drug Substance [Member]
Significant Accounting Policies [Line Items]
Total proceeds from accounts receivable outstanding - Pfizer						$ 1.3
Private Placement [Member]
Significant Accounting Policies [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001
Number of shares issued (in shares)	17,604,423
Par value (in dollars per share)	$ 0.001
Purchase price (in dollars per share)	$ 2.485
Number of warrants issued (in shares)	17,604,423
Exercise price of warrants (in dollars per share)	$ 2.36
Exercise of warrants, commencement period	6 months
Term of warrants	5 years
Reverse stock split ratio		1-for-10
Receivable from issuance of common stock and warrants							$ 1.0
Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]
Significant Accounting Policies [Line Items]
Collaborative Arrangement Revenues and Expenses Sharing Percentage					100.00%
Chiesi US Agreement [Member]
Significant Accounting Policies [Line Items]
Upfront Nonrefundable Non-Creditable Payment Receivable			$ 25.0
Additional Amounts Payable To Cover Development Costs			20.0
Maximum Entitlement Of Development Costs To Cover Per Year			7.5
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones			$ 760.0
Chiesi US Agreement [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage			15.00%
Chiesi US Agreement [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage			40.00%
Chiesi Ex US Agreement [Member]
Significant Accounting Policies [Line Items]
Upfront Nonrefundable Non-Creditable Payment Receivable				$ 25.0
Additional Amounts Payable To Cover Development Costs				25.0
Maximum Entitlement Of Development Costs To Cover Per Year				10.0
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones				$ 320.0
Chiesi Ex US Agreement [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage				15.00%
Chiesi Ex US Agreement [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage				35.00%